Protalix (PLX) AI Stock Analysis

• Market Cap: $217.08M
• Dividend Yield: N/A
• Average Volume (3M): 705.35K
• Price to Earnings (P/E): 103.8
• Beta (1Y): 0.45
• Revenue Growth: -18.47%
• EPS Growth: -70.64%
• Country: US
• Employees: 213
• Sector: Healthcare
• Sector Strength: 54
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 79,517,140
• 10 Day Avg. Volume: 959,185
• 30 Day Avg. Volume: 705,348
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 3.90
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.00
• Price Target Upside: 419.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Protalix's stock is buoyed by strong financial and technical performance, with significant revenue growth and positive technical indicators. However, high leverage, valuation concerns, and recent earnings call highlights such as declining R&D revenues and lower net income present challenges.

Positive Factors

Financial Performance

Capital structure now looks exceptionally clean, with no remaining long-term debt outstanding.

Market Opportunity

Protalix management indicated that the total Fabry disease market opportunity may raise to $3.1B by 2030, with the potential for the royalty stream from Elfabrio to reach $120-150M per year to the company.

Regulatory Approval

Elfabrio is approved across 23 territories globally for the treatment of Fabry disease and offers safety and convenience advantages.

Negative Factors

Drug Tolerability

PRX–115 was found to be well-tolerated, with only 25% of the subjects treated with PRX–115 in the study having reported study drug-related adverse events, the majority of which were mild to moderate and transient in nature.

Protalix Business Overview & Revenue Model

Company Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

How the Company Makes Money

Protalix generates revenue primarily through the development and commercialization of its proprietary therapeutic proteins. The company makes money by entering into licensing agreements and collaborations with larger pharmaceutical companies, which often include upfront payments, milestone payments, and royalties on sales of products developed using its technology. Protalix's revenue streams are significantly influenced by these partnerships, as well as the commercialization of its own products. Additionally, the company may receive government grants and incentives for research and development activities within the biotechnology sector.

Protalix Financial Statement Overview

Summary

Protalix has shown substantial improvements in profitability and cash flow, crucial for its financial stability. While revenue growth has been inconsistent and leverage remains a concern, the positive momentum in financial health is evident. Continued focus on reducing debt and enhancing revenue will be key.

Income Statement

The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.

Balance Sheet

Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.

Cash Flow

The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
53.40M	65.49M	47.64M	38.35M	62.90M
	Gross Profit
29.08M	42.51M	28.05M	22.00M	52.02M
	EBIT
3.92M	10.46M	-13.01M	-20.46M	1.85M
	EBITDA
6.52M	11.65M	-10.78M	-18.94M	4.45M
	Net Income Common Stockholders
2.93M	8.31M	-14.93M	-33.98M	-14.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
34.83M	44.56M	22.18M	38.98M	38.55M
	Total Assets
73.42M	84.43M	55.79M	73.67M	67.93M
	Total Debt
5.53M	26.28M	33.47M	33.47M	64.40M
	Net Debt
-14.23M	2.65M	16.36M	-5.51M	46.13M
	Total Liabilities
30.21M	50.87M	66.43M	79.70M	94.97M
	Stockholders Equity
43.21M	33.57M	-10.64M	-6.04M	-27.04M
Cash Flow		Free Cash Flow
7.39M	-2.47M	-25.63M	-11.74M	-26.76M
	Operating Cash Flow
8.67M	-1.32M	-25.00M	-10.29M	-26.11M
	Investing Cash Flow
4.22M	-16.71M	-5.04M	18.92M	-19.95M
	Financing Cash Flow
-16.79M	24.67M	8.24M	12.08M	46.47M

Protalix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Positive. The current price of 2.89 is above the 20-day moving average (MA) of 2.76, above the 50-day MA of 2.54, and above the 200-day MA of 1.78, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 57.61 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLX.

Protalix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	66 Neutral	$217.08M	103.80	7.64%	―	-18.47%	-70.64%
DBVT	55 Neutral	$266.68M	―	-198.47%	―	―	-38.74%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
LXRX	50 Neutral	$238.21M	―	-167.66%	―	2479.34%	18.91%
TERN	45 Neutral	$262.88M	―	-29.56%	―	―	10.98%
HURA	36 Underperform	$162.93M	―	-203.07%	―	―	77.12%
GOSS	35 Underperform	$247.67M	―	-122.54%	―	―	81.94%

Protalix Corporate Events

Protalix CFO Eyal Rubin Announces Resignation

On April 21, 2025, Eyal Rubin, the Senior Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., announced his resignation to pursue other opportunities, effective in six months. During his tenure, Rubin significantly contributed to the company’s financial and product development advancements. He will continue in his role during the transition period, receiving full salary and benefits, and will be entitled to severance and accelerated equity vesting upon his departure.

Spark’s Take on PLX Stock

According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.

Protalix’s overall score reflects strong technical momentum and positive corporate developments, such as debt repayment and operational achievements. However, financial performance and valuation challenges, including inconsistent revenue growth and a negative P/E ratio, temper the outlook. Continued focus on revenue enhancement and debt reduction will be crucial for future performance.

To see Spark’s full report on PLX stock, click here.